Trending Now
Selecta Biosciences Inc. (NASDAQ:SELB) And Swedish Orphan Biovitrum To Advance Development...
Selecta Biosciences Inc. (NASDAQ:SELB) and Swedish Orphan Biovitrum AB (SOBI) have entered a strategic licensing agreement for advancing the development of SEL-212, which is...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Sorrento Therapeutics Inc. (NASDAQ: SRNE) Receives GMP Approval For COVISTIX From...
Sorrento Therapeutics Inc. (NASDAQ: SRNE) has received approval for COVISTIX from the Brazilian regulatory agency (ANVISA). COVISTIX is a diagnostic tool that has the...
MAKE IT MODERN
LATEST REVIEWS
Axsome Therapeutics Inc. (NASDAQ:AXSM) Announces Development Status For AXS-05 In The...
There are hundreds of people facing unsatisfactory treatments for CNS disorders. Due to the limitation of treatment options, Axsome Therapeutics Inc (NASDAQ:AXSM) has taken...
MAKE IT MODERN
PERFORMANCE TRAINING
Novo Integrated Sciences Inc (NASDAQ: NVOS) Announces Board Changes and Receives Confirmation of Promissory...
Novo Integrated Sciences Inc (NASDAQ: NVOS), a prominent player in the healthcare and medical sciences sector, recently made two significant announcements that...
Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Gets Accelerated Response From FDA Regarding TSC Clinical Study In...
Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) has announced that the FDA has granted it accelerated response regarding its pre-investigational New Drug meeting request.
FDA gives Diffusion accelerated...
Aptose Biosciences Inc.’s (NASDAQ: APTO) HM43239 Shows Durable Activity In Refractory/Relapsed Acute Myeloid Leukemia
Aptose Biosciences Inc. (NASDAQ: APTO) has announced that oral myeloid kinome inhibitor HM43239 has shown durable single-agent activity in refractory/relapsed acute myeloid leukemia patients....
Aravive Inc (NASDAQ: ARAV) Reports Improved Tolerability In Patients With Advanced Stage Kidney Cancer...
Aravive Inc (NASDAQ: ARAV) posted an initial readout of the positive results from the phase 1b clinical study of AVB-500 in combination therapy with...
Aptose Biosciences (NASDAQ:APTO) Announce Dosing of First AML Patient In CG-806 Study
Aptose Biosciences Inc. (NASDAQ:APTO) has announced the dosing of the first acute myeloid leukemia (AML) patient in Phase 1 a/b CG-806 clinical study.
CG-806 inhibits...
MAKE IT MODERN
